Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-t...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.676973/full |
id |
doaj-2055b3371b7f4a068ee6fa36f91423f0 |
---|---|
record_format |
Article |
spelling |
doaj-2055b3371b7f4a068ee6fa36f91423f02021-04-15T08:51:30ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-04-011210.3389/fendo.2021.676973676973Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine TumorsElena María Vida Navas0Alberto Martínez Lorca1Aintzane Sancho Gutiérrez2Lucia Sanz Gómez3Teresa Navarro Martínez4Enrique Grande Pulido5Alfredo Carrato Mena6Pablo Gajate Borau7Medical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, SpainNuclear Medicine Department, Hospital Universitario Ramón y Cajal, Madrid, SpainMedical Oncology Department, Hospital Universitario Cruces, Baracaldo, SpainMedical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, SpainNuclear Medicine Department, Hospital Universitario Ramón y Cajal, Madrid, SpainMedical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, SpainMedical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, SpainMedical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, SpainPeptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-treated with 177Lu-DOTATATE and a literature review about salvage treatment with PRRT. We present a 26-year-old man who started with pelvic pain and after a biopsy of a retro-rectal mass observed in a magnetic resonance was diagnosed with an advanced neuroendocrine tumour. After progression to lanreotide, everolimus and sunitinib, treatment with 177Lu-DOTATATE was initiated, achieving an excellent response with a progression free survival (PFS) of 38 months. At the time of progression, re-treatment with 177Lu-DOTATATE was decided, showing a new partial response, which is currently stable after 15 months. The patient had not presented significant treatment-related toxicity. Although there are no randomized phase III trials or a consensus about the number or dose of cycles, there is evidence about the efficacy and low toxicity of salvage treatment with 177Lu-DOTATATE in NETs. Median progression-free survival ranges from 6 to 22 months. Toxicity is mostly hematologic (anemia and neutropenia), 4-7% grade 3/4.https://www.frontiersin.org/articles/10.3389/fendo.2021.676973/fullneuroendocrine tumorsLu-DOTATATEneuroendocrine neoplasmspeptide receptor radionuclide therapycase report |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena María Vida Navas Alberto Martínez Lorca Aintzane Sancho Gutiérrez Lucia Sanz Gómez Teresa Navarro Martínez Enrique Grande Pulido Alfredo Carrato Mena Pablo Gajate Borau |
spellingShingle |
Elena María Vida Navas Alberto Martínez Lorca Aintzane Sancho Gutiérrez Lucia Sanz Gómez Teresa Navarro Martínez Enrique Grande Pulido Alfredo Carrato Mena Pablo Gajate Borau Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors Frontiers in Endocrinology neuroendocrine tumors Lu-DOTATATE neuroendocrine neoplasms peptide receptor radionuclide therapy case report |
author_facet |
Elena María Vida Navas Alberto Martínez Lorca Aintzane Sancho Gutiérrez Lucia Sanz Gómez Teresa Navarro Martínez Enrique Grande Pulido Alfredo Carrato Mena Pablo Gajate Borau |
author_sort |
Elena María Vida Navas |
title |
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors |
title_short |
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors |
title_full |
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors |
title_fullStr |
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors |
title_full_unstemmed |
Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors |
title_sort |
case report: re-treatment with lu-dotatate in neuroendocrine tumors |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Endocrinology |
issn |
1664-2392 |
publishDate |
2021-04-01 |
description |
Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-treated with 177Lu-DOTATATE and a literature review about salvage treatment with PRRT. We present a 26-year-old man who started with pelvic pain and after a biopsy of a retro-rectal mass observed in a magnetic resonance was diagnosed with an advanced neuroendocrine tumour. After progression to lanreotide, everolimus and sunitinib, treatment with 177Lu-DOTATATE was initiated, achieving an excellent response with a progression free survival (PFS) of 38 months. At the time of progression, re-treatment with 177Lu-DOTATATE was decided, showing a new partial response, which is currently stable after 15 months. The patient had not presented significant treatment-related toxicity. Although there are no randomized phase III trials or a consensus about the number or dose of cycles, there is evidence about the efficacy and low toxicity of salvage treatment with 177Lu-DOTATATE in NETs. Median progression-free survival ranges from 6 to 22 months. Toxicity is mostly hematologic (anemia and neutropenia), 4-7% grade 3/4. |
topic |
neuroendocrine tumors Lu-DOTATATE neuroendocrine neoplasms peptide receptor radionuclide therapy case report |
url |
https://www.frontiersin.org/articles/10.3389/fendo.2021.676973/full |
work_keys_str_mv |
AT elenamariavidanavas casereportretreatmentwithludotatateinneuroendocrinetumors AT albertomartinezlorca casereportretreatmentwithludotatateinneuroendocrinetumors AT aintzanesanchogutierrez casereportretreatmentwithludotatateinneuroendocrinetumors AT luciasanzgomez casereportretreatmentwithludotatateinneuroendocrinetumors AT teresanavarromartinez casereportretreatmentwithludotatateinneuroendocrinetumors AT enriquegrandepulido casereportretreatmentwithludotatateinneuroendocrinetumors AT alfredocarratomena casereportretreatmentwithludotatateinneuroendocrinetumors AT pablogajateborau casereportretreatmentwithludotatateinneuroendocrinetumors |
_version_ |
1721526395453046784 |